NEW YORK, Sept. 27, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Pharmacovigilance and Related Developments 2011-2021
http://www.reportlinker.com/p0629364/Pharmacovigilance-and-Related-Developments-2011-2021.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory
Report Details
What does the future hold for pharmacovigilance? Visiongain's new report shows you prospects to 2021, discussing opportunities and developments. Find data you need.
Assess events, opportunities and activities shaping pharmacovigilance to 2021: regulations, technologies and services. Through our research and analysis we aim to save you time and help in your decisions.
How will changes affect pharmacovigilance? What are drug producers and service providers doing? What regulations and technologies influence that field? Our study explains, showing you developments and opportunities.
Pharmacovigilance will become more important during this decade. You can discover spending forecasts for pharmacovigilance. Find data and discussions for the overall world market, the US, the EU and Japan.
Discover pharmacovigilance activities of Pfizer, J&J, GSK, Sanofi, Novartis, AstraZeneca, Roche, Abbott, Eli Lilly and Bristol-Myers Squibb. You can find trends and prospects.
Assess leading companies offering pharmacovigilance services - Oracle, Aris Global, NDA, PharSafer Associates and PrimeVigilance. See what activities are shaping the field.
Our new report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. To get that information please respond now.
Analysis with potential future trends, revenue predictions, opinions and discussions
In our report you find revenue forecasts, growth rates, market shares, qualitative analyses, opinions from our survey and discussions of regulations and companies. You receive 56 tables and charts and three research interviews (see the accompanying lists).
Pharmacovigilance and Related Developments 2011-2021 shows you opportunities, challenges and forecasts
Our report gives you the following advantages in particular:
• Receive wide-ranging data and discussions for pharmacovigilance, seeing the relevance of regulations and practices
• Assess the activities of top pharma companies and leading service providers
• Discover a forecast for world pharmacovigilance spending to 2021, seeing trends
• Find pharmacovigilance spending forecasts to 2021 for the US, the EU and Japan
• Receive a forecast to 2021 for R&D spending in the world pharma industry
• Investigate driving and restraining forces in pharmacovigilance, seeing opportunities
• Assess the implications of pharmacovigilance for stakeholders - drug manufacturers, pharma regulators, prescribers, payers and patients
• View opinion from our survey of the industry, with three full interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions in pharmacovigilance, helping you to stay ahead.
Order our report now to gain industry and market analysis for pharmacovigilance
Our report is for everybody needing industry and market analysis for pharmacovigilance. Find trends and answers. Avoid missing out - please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Companies Listed
Abbott Laboratories
Acorda Therapeutics
Agencia Nacional de Vigilancia Sanitaria [Brazil]
Alexion Europe SAS
Aris Global
Asia-Pacific Economic Cooperation (APEC)
Association of British Pharmaceutical Industries (ABPI)
Association of British Pharmaceutical Industries' Pharmacovigilance Expert Network
Association of the Southeast Asian Nations (ASEAN)
AstraZeneca
Brazilian Health Surveillance Agency [Brazil]
Bristol-Myers Squibb
Bureau of Pharmaceutical Affairs (Department of Health) [Chinese Taipei]
Center for Biologics Evaluation and Research (CBER) [USA]
Center for Devices and Radiological Health (CDRH) [USA]
Centers for Disease Control and Prevention
Center for Drug Evaluation and Research (CDER) [USA]
Center for Food Safety and Applied Nutrition (CFSAN) [USA]
Center for Veterinary Medicine (CVM) [USA]
Cerner Galt
ClinicalTrials
Commission on Human Medicines
Committee for Medicinal Products for Human Use (CHMP)
Committee on the Safety of Medicine
Contergan Foundation
Council for International Organization of Medical Sciences
Covectra
Department of Drug Registration (State Food and Drug Administration) [China]
Department of Health and Ageing [Australia]
Department of International Cooperation (State Food of Drug Administration) [China]
Division of Medical Products Registration [Russia]
Division of Pharmaceutical Chemistry (Department of Health) [Chinese Taipei]
Drug Evaluation Department (Korea Food and Drug Administration [KFDA]) [South Korea]
Drug Logic
Drug Safety Research Unit
Eli Lilly
Elliot Brown Consulting
Eudravigilance Database
European Commission
European Council
European Economic Area
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Free Trade Association
European Pharmacovigilance Guidelines
European Medicines Agency (EMA)
European Medicines Evaluation Agency
European Parliament
Federal Association of Thalidomide Victims
Federal Service on Surveillance in Healthcare and Social Development [Russia]
Food and Drug Administration (US FDA)
Food and Drug Administration Sentinel Initiative
Genentech
GlaxoSmithKline (GSK)
Grünenthal
Gulf Cooperation Council (GCC)
Health Products Regulation Group (Health Sciences Authority) [Singapore]
Health Sciences Authority [Singapore]
Homeland Security Advisory System
Human Genome Project
ICH Global Cooperation Group
iGuard
Imperial Chemical Industries (ICI)
Imperial College London
Innovative Medicines Initiative
Intensive Medicine s Monitoring Programme
International Conference on Harmonisation (ICH)
Ion Torrent
Japan Pharmaceutical Manufacturers Association (JPMA)
Johnson & Johnson
J-PEM
Korea Food and Drug Administration [South Korea]
Medicines and Healthcare Products Regulatory Agency (MHRA)
Medicines Monitoring Programme
MediGuard
MedWatch
MedImmune Patient Safety
Merck & Co.
Ministry of Health and Welfare [India]
Ministry of Health, Labour and Welfare (MHLW) [Japan]
National Center for Toxicological Research (NCTR) [USA]
National Institute for Clinical Excellence (NICE) [UK]
National Patient Safety Agency (NPSA)
NDA
NDA Regulatory Science
Novartis
Office of Prescription Medicines [Australia]
Office of Regulatory Affairs (ORA) [USA]
Office of the Commissioner (OC) [USA]
Oracle
Pan American Network for Drug Regulatory Harmonisation (PANDRH)
Pfizer
Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
Pharmaceutical Research and Manufacturers of America (PhRMA)
Pharmaceuticals and Biologics Branch (Health Sciences Authority) [Singapore]
PharSafer Associates
Phase Forward
PrimeVigilance
PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium)
Quintiles Transnational
Roche
Sanofi
SaPhar
Serious Adverse Event Consortium
Southern African Development Community (SADC)
State Food and Drug Administration [China]
Tata Consultancy Services
The White House Office of National Drug Control Policy
The Observer
UK Government
Uppsala Monitoring Centre (UMC)
US Federal Government
VIGOR Study
WHO Collaborating Centre for International Drug Monitoring
World Health Organization (WHO)
To order this report:
: Pharmacovigilance and Related Developments 2011-2021
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker